Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Incyte Corp (INCY)

Incyte Corp (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,439,896
  • Shares Outstanding, K 219,923
  • Annual Sales, $ 2,667 M
  • Annual Income, $ -295,700 K
  • 60-Month Beta 0.80
  • Price/Sales 6.48
  • Price/Cash Flow N/A
  • Price/Book 6.34
Trade INCY with:

Options Overview

Details
  • Implied Volatility 32.37%
  • Historical Volatility 14.96%
  • IV Percentile 4%
  • IV Rank 14.20%
  • IV High 59.10% on 03/05/21
  • IV Low 27.94% on 06/25/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 279
  • Volume Avg (30-Day) 281
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 29,082
  • Open Int (30-Day) 29,171

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.55
  • Number of Estimates 4
  • High Estimate 0.66
  • Low Estimate 0.40
  • Prior Year 1.04
  • Growth Rate Est. (year over year) -47.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.30 +2.59%
on 07/19/21
88.26 -10.15%
on 06/28/21
-5.83 (-6.85%)
since 06/23/21
3-Month
77.30 +2.59%
on 07/19/21
88.26 -10.15%
on 06/28/21
-6.28 (-7.34%)
since 04/23/21
52-Week
75.52 +5.01%
on 03/04/21
102.68 -22.77%
on 07/27/20
-22.38 (-22.01%)
since 07/23/20

Most Recent Stories

More News
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its Biologics License Application (BLA) for retifanlimab,...

INCY : 79.30 (+0.86%)
REGN or INCY: Which Is the Better Value Stock Right Now?

REGN vs. INCY: Which Stock Is the Better Value Option?

REGN : 586.35 (-0.09%)
INCY : 79.30 (+0.86%)
Big Rebound as Fear Subsides and Netflix Reports

Big Rebound as Fear Subsides and Netflix Reports

ASPU : 6.77 (-3.15%)
MTDR : 30.78 (-2.81%)
NEP : 74.30 (-0.59%)
SIG : 67.23 (+0.48%)
PLBY : 28.24 (+3.03%)
MAXR : 34.16 (-1.73%)
GDRX : 31.88 (+1.30%)
DAL : 40.41 (-1.58%)
CHGG : 88.06 (+1.62%)
INCY : 79.30 (+0.86%)
MRVL : 58.92 (+1.62%)
STNE : 59.46 (+1.52%)
TMUS : 144.00 (-0.52%)
TRIP : 36.26 (+0.55%)
RAIL : 5.45 (-2.85%)
SAVA : 123.38 (-2.55%)
AA : 37.06 (-0.46%)
NFLX : 515.41 (+0.71%)
JNJ : 171.79 (+1.06%)
TXN : 186.85 (+1.60%)
CSX : 32.81 (+0.43%)
AbbVie (ABBV) Rinvoq Dermatitis' sNDA Decision Delayed by FDA

The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.

PFE : 41.68 (+0.51%)
LLY : 244.15 (+2.37%)
INCY : 79.30 (+0.86%)
ABBV : 118.19 (+0.55%)
Lilly (LLY), Incyte's Decision on Olumiant sNDA Delayed by FDA

The FDA will not meet the PDUFA action date for Lilly (LLY) and Incyte's (INCY) sNDA for Olumaint to treat adults with atopic dermatitis.

LLY : 244.15 (+2.37%)
BAYRY : 14.9700 (-0.20%)
INCY : 79.30 (+0.86%)
ABBV : 118.19 (+0.55%)
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action...

LLY : 244.15 (+2.37%)
INCY : 79.30 (+0.86%)
Incyte to Report Second Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 3, 2021.

INCY : 79.30 (+0.86%)
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi(R)) in Chronic Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM) demonstrating that treatment with ruxolitinib (Jakafi(R))...

INCY : 79.30 (+0.86%)
Incyte's (INCY) Lymphoma Drug Obtains Positive CHMP Opinion

Incyte (INCY) and MorphoSys (MOR) receive positive CHMP opinion for tafasitamab in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma....

NVS : 91.57 (+0.54%)
BMY : 68.34 (+0.56%)
INCY : 79.30 (+0.86%)
MOR : 16.18 (-0.74%)
REGN vs. INCY: Which Stock Is the Better Value Option?

REGN vs. INCY: Which Stock Is the Better Value Option?

REGN : 586.35 (-0.09%)
INCY : 79.30 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Their first commercial product, Jakafi (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis...

See More

Key Turning Points

3rd Resistance Point 80.89
2nd Resistance Point 80.26
1st Resistance Point 79.78
Last Price 79.30
1st Support Level 78.67
2nd Support Level 78.04
3rd Support Level 77.56

See More

52-Week High 102.68
Fibonacci 61.8% 92.30
Fibonacci 50% 89.10
Fibonacci 38.2% 85.90
Last Price 79.30
52-Week Low 75.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar